Use caution in patients with mild to moderate hepatic impairment (Child-Pugh class B); use unboosted atazanavir only; dose adjustments recommended for treatment-naive patients.
Use caution in patients with preexisting conduction system disease; monitoring recommended.
Consider alternative treatment options in high risk renal patients; monitoring recommended and discontinuation may be required.
Use is not recommended in HIV treatment-experienced patients with end-stage renal disease managed by hemodialysis.
Discontinue if severe rash develops.
Initiation or dose adjustment of insulin or oral hypoglycemic agent may be required.